Shanghai InnoStar Bio-tech Co., Ltd. (SHA:688710)
China · Delayed Price · Currency is CNY 90.10
+6.74 (8.09%)
At close: Oct 28, 2026
SHA:688710 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,026 | 810.52 | 1,141 | 1,036 | 862.21 | 581.62 |
Other Revenue | 0.81 | 0.81 | 0.99 | 2.02 | 0.86 | 0.15 |
| 1,027 | 811.33 | 1,142 | 1,038 | 863.07 | 581.77 | |
Revenue Growth | 23.75% | -28.93% | 9.94% | 20.32% | 48.35% | 74.30% |
Cost of Revenue | 779.92 | 670.4 | 807.21 | 628.19 | 535.88 | 362.59 |
Gross Profit | 247.1 | 140.93 | 334.46 | 410.24 | 327.2 | 219.18 |
Selling, General & Admin | 139.57 | 143.77 | 144.89 | 165.38 | 168.11 | 118.78 |
Research & Development | 53.45 | 44.76 | 58.31 | 58.23 | 49.51 | 26.81 |
Other Operating Expenses | 0.77 | -11.39 | -21.66 | -3.41 | -32.06 | -37.04 |
Operating Expenses | 194.48 | 181.58 | 185.86 | 221.68 | 190.26 | 112.28 |
Operating Income | 52.62 | -40.65 | 148.6 | 188.56 | 136.94 | 106.9 |
Interest Expense | -1.48 | -8.54 | -11.67 | -12.01 | -13.42 | -10.99 |
Interest & Investment Income | 4.22 | 17.1 | 21.52 | 20.16 | 17.83 | 6.21 |
Currency Exchange Gain (Loss) | 0.02 | 0.02 | 0.78 | -0.37 | - | - |
Other Non Operating Income (Expenses) | -2.74 | -2 | -0.17 | -0.2 | 1.33 | -0.14 |
EBT Excluding Unusual Items | 52.63 | -34.08 | 159.06 | 196.14 | 142.68 | 101.98 |
Gain (Loss) on Sale of Assets | 2.1 | 21.2 | -0 | -0 | 0.21 | - |
Asset Writedown | 19.07 | -1.92 | - | - | -1.1 | -0 |
Other Unusual Items | 7.25 | -1.49 | -0.25 | 15.55 | - | - |
Pretax Income | 81.04 | -16.3 | 158.81 | 211.68 | 141.79 | 101.98 |
Income Tax Expense | 7.21 | -5.81 | 22.26 | 30.17 | 23.64 | 9.5 |
Earnings From Continuing Operations | 73.83 | -10.48 | 136.55 | 181.52 | 118.16 | 92.48 |
Minority Interest in Earnings | 4.45 | -20.03 | 11.23 | 12.93 | 17.25 | 2.21 |
Net Income | 78.29 | -30.52 | 147.78 | 194.45 | 135.41 | 94.69 |
Net Income to Common | 78.29 | -30.52 | 147.78 | 194.45 | 135.41 | 94.69 |
Net Income Growth | 38192.09% | - | -24.00% | 43.60% | 43.01% | 95.21% |
Shares Outstanding (Basic) | 133 | 139 | 117 | 106 | 97 | 73 |
Shares Outstanding (Diluted) | 133 | 139 | 117 | 106 | 97 | 73 |
Shares Change | -8.81% | 18.27% | 10.98% | 9.26% | 31.77% | 24.09% |
EPS (Basic) | 0.59 | -0.22 | 1.26 | 1.84 | 1.40 | 1.29 |
EPS (Diluted) | 0.59 | -0.22 | 1.26 | 1.84 | 1.40 | 1.29 |
EPS Growth | 41902.14% | - | -31.52% | 31.43% | 8.53% | 57.32% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 207.36 | -32.57 | -384.15 | -65.85 | 132.67 | 44.33 |
Free Cash Flow Per Share | 1.56 | -0.23 | -3.27 | -0.62 | 1.37 | 0.60 |
Dividend Per Share | - | - | 0.320 | - | - | 0.350 |
Dividend Growth | - | - | - | - | - | 105.88% |
Gross Margin | 24.06% | 17.37% | 29.30% | 39.51% | 37.91% | 37.67% |
Operating Margin | 5.12% | -5.01% | 13.02% | 18.16% | 15.87% | 18.38% |
Profit Margin | 7.62% | -3.76% | 12.94% | 18.73% | 15.69% | 16.28% |
Free Cash Flow Margin | 20.19% | -4.01% | -33.65% | -6.34% | 15.37% | 7.62% |
EBITDA | 122.58 | 21.02 | 199.23 | 235.8 | 179.75 | 139.95 |
EBITDA Margin | 11.94% | 2.59% | 17.45% | 22.71% | 20.83% | 24.05% |
D&A For EBITDA | 69.96 | 61.68 | 50.63 | 47.24 | 42.82 | 33.05 |
EBIT | 52.62 | -40.65 | 148.6 | 188.56 | 136.94 | 106.9 |
EBIT Margin | 5.12% | -5.01% | 13.02% | 18.16% | 15.87% | 18.38% |
Effective Tax Rate | 8.89% | - | 14.02% | 14.25% | 16.67% | 9.32% |
Revenue as Reported | 240.64 | 811.33 | 1,142 | 1,038 | 863.07 | - |
Advertising Expenses | - | 0.62 | 1.14 | 1.84 | 0.34 | - |